Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ).
Shanghai Haohai Biological Technology Co., Ltd. has announced a 2025 first H shareholders’ class meeting scheduled for June 10, 2025, following their 2024 annual general meeting. During this meeting, a special resolution will be considered to grant the Board a general mandate to repurchase up to 10% of the H Shares in issue. This move is aimed at optimizing the company’s capital structure and enhancing shareholder value, reflecting strategic positioning in the market.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the biotechnology industry. The company is involved in the development and production of biological products, leveraging advanced technologies to cater to various market needs.
Average Trading Volume: 585,957
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.06B
For a thorough assessment of 6826 stock, go to TipRanks’ Stock Analysis page.